Journal of Thoracic Oncology最新文献

{"title":"A Response to the Letter to the Editor: MARS2 Perspective","authors":"Harvey I. Pass MD, Eric Lim MD, Isabelle Opitz MD, Gavitt Woodard MD, Raphael Bueno MD, Marc de Perrot MD, Raja Flores MD, Ritu Gill MD, David Jablons MD","doi":"10.1016/j.jtho.2025.02.018","DOIUrl":"10.1016/j.jtho.2025.02.018","url":null,"abstract":"","PeriodicalId":17515,"journal":{"name":"Journal of Thoracic Oncology","volume":"20 5","pages":"Pages e60-e61"},"PeriodicalIF":21.0,"publicationDate":"2025-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143916810","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Advancing the Needle on the Management of Resectable EGFR-Positive NSCLC: Is Neoadjuvant Osimertinib the Answer?","authors":"Cathleen June Park MD , Stephanie Pei Li Saw MD","doi":"10.1016/j.jtho.2025.02.007","DOIUrl":"10.1016/j.jtho.2025.02.007","url":null,"abstract":"","PeriodicalId":17515,"journal":{"name":"Journal of Thoracic Oncology","volume":"20 5","pages":"Pages 542-545"},"PeriodicalIF":21.0,"publicationDate":"2025-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143917232","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The Tree That Let Us See the Forest: The Importance of Comorbidities in Lung Cancer Screening Programs","authors":"Juan P. de-Torres MD , Nerea Varo MD","doi":"10.1016/j.jtho.2025.01.015","DOIUrl":"10.1016/j.jtho.2025.01.015","url":null,"abstract":"","PeriodicalId":17515,"journal":{"name":"Journal of Thoracic Oncology","volume":"20 5","pages":"Pages 555-556"},"PeriodicalIF":21.0,"publicationDate":"2025-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143917235","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The International Association for the Study of Lung Cancer Lung Cancer Staging Project: Application and Interpretation of the Residual Tumor Classification for Lung Cancer—Results from an International Survey Among Pathologists and Thoracic Surgeons","authors":"Hans Hoffmann MD ,&nbsp;Andrew G. Nicholson DM, FRCPath ,&nbsp;Frank C. Detterbeck MD ,&nbsp;Ming S. Tsao MD, FRCPC ,&nbsp;Marcin Ostrowski MD ,&nbsp;Ramón Rami-Porta MD, FETCS ,&nbsp;Alain Borczuk MD ,&nbsp;Mirella Marino MD ,&nbsp;William D. Travis MD ,&nbsp;Paul E. Van Schil MD, PhD ,&nbsp;John Edwards FRCS(C/Th), MD ,&nbsp;Members of the R-Subcommittee, the IASLC Staging and Prognostic Factors Committee, and the Advisory Boards","doi":"10.1016/j.jtho.2024.12.007","DOIUrl":"10.1016/j.jtho.2024.12.007","url":null,"abstract":"<div><h3>Objectives</h3><div>The study aimed to assess the opinion of pathologists and thoracic surgeons of the International Association for the Study of Lung Cancer regarding the application and interpretation of the residual tumor (R) classification for lung cancer.</div></div><div><h3>Methods</h3><div>On the basis of their membership profiles, a total of 623 pathologists and thoracic surgeons were identified and contacted by email with a cover letter and a link to an online survey. The questionnaire consisted of 12 questions about various aspects of the application and interpretation of the R classification for lung cancer. The response rate (to at least one question) was 72% (144 pathologists and 303 surgeons).</div></div><div><h3>Results</h3><div>The frequency of use of the R classification varies by geographic region. Although R status is regularly reported in Europe and Asia, 70% of pathologists in the United States and Canada never include R status in reports. Similar variations exist about who assigns the R category for the resection—in Europe and the United Kingdom, it is mainly the pathologist, whereas in China, Japan and the United States, it is the surgeon. There are some good agreements about margins examined and how to manage staple lines. The category “uncertain resection” has not been practically implemented in most of the world, except at some centers in Japan and the United Kingdom.</div></div><div><h3>Conclusion</h3><div>This survey shows that surgical resection margins are part of routine reporting in most institutions; but the assignment of an R category is not always part of the pathology report, with considerable variation between countries. Despite the International Association for the Study of Lung Cancer proposals, the application of the uncertain resection category has not been taken up by most institutions, and further evidence is needed.</div></div>","PeriodicalId":17515,"journal":{"name":"Journal of Thoracic Oncology","volume":"20 5","pages":"Pages 597-613"},"PeriodicalIF":21.0,"publicationDate":"2025-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142828810","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Diabetic Ketoacidosis During Lorlatinib Treatment: Case Report","authors":"Atsushi Yanagisawa MD,&nbsp;Takayuki Shiroyama MD, PhD,&nbsp;Kotaro Miyake MD, PhD,&nbsp;Yoshito Takeda MD, PhD,&nbsp;Atsushi Kumanogoh MD, PhD","doi":"10.1016/j.jtho.2025.01.010","DOIUrl":"10.1016/j.jtho.2025.01.010","url":null,"abstract":"<div><div>Although hyperlipidemia is a well-known adverse event associated with lorlatinib treatment, lorlatinib-associated hyperglycemia is less common but can be potentially life-threatening. We present the case of a 65-year-old male patient with anaplastic lymphoma kinase–positive lung cancer and preexisting type 2 diabetes mellitus who developed diabetic ketoacidosis (DKA) after switching from alectinib to lorlatinib. After initiating lorlatinib treatment, the patient’s glycemic control deteriorated rapidly, with the glycated hemoglobin levels increasing from 6% to 11.5% within three months. The patient was admitted and received intensive insulin therapy along with temporary discontinuation of lorlatinib, which successfully resolved DKA. After a 2-week interruption, lorlatinib was resumed at a reduced dose with satisfactory glycemic control. This case highlights the importance of vigilant glucose monitoring for patients receiving lorlatinib, especially those with preexisting diabetes, to prevent life-threatening complications such as DKA.</div></div>","PeriodicalId":17515,"journal":{"name":"Journal of Thoracic Oncology","volume":"20 5","pages":"Pages 676-679"},"PeriodicalIF":21.0,"publicationDate":"2025-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143074940","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Tobacco News Update — From the IASLC Tobacco Control Committee","authors":"","doi":"10.1016/j.jtho.2025.03.038","DOIUrl":"10.1016/j.jtho.2025.03.038","url":null,"abstract":"","PeriodicalId":17515,"journal":{"name":"Journal of Thoracic Oncology","volume":"20 5","pages":"Pages 539-541"},"PeriodicalIF":21.0,"publicationDate":"2025-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143916817","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"A Prospective Phase II Trial of First-Line Osimertinib for Patients With EGFR Mutation-Positive NSCLC and Poor Performance Status (OPEN/TORG2040)","authors":"Tomoya Fukui MD, PhD ,&nbsp;Nobuaki Mamesaya MD, PhD ,&nbsp;Toshiaki Takahashi MD, PhD ,&nbsp;Kazuma Kishi MD ,&nbsp;Takahiro Yoshizawa MD ,&nbsp;Takaaki Tokito MD, PhD ,&nbsp;Koichi Azuma MD ,&nbsp;Kei Morikawa MD ,&nbsp;Satoshi Igawa MD, PhD ,&nbsp;Yusuke Okuma MD ,&nbsp;Yuta Yamanaka MD ,&nbsp;Shinobu Hosokawa MD, PhD ,&nbsp;Takashi Kasai MD ,&nbsp;Ken Masubuchi MD ,&nbsp;Shinji Nakamichi MD, PhD ,&nbsp;Masaharu Aga MD ,&nbsp;Jiichiro Sasaki MD, PhD ,&nbsp;Akiko Kada MPH ,&nbsp;Akiko M. Saito MD, PhD ,&nbsp;Katsuhiko Naoki MD, PhD ,&nbsp;Hiroaki Okamoto MD, PhD","doi":"10.1016/j.jtho.2024.12.027","DOIUrl":"10.1016/j.jtho.2024.12.027","url":null,"abstract":"<div><h3>Introduction</h3><div>Osimertinib is the first-line treatment for patients with NSCLC who have <em>EGFR</em> mutations and favorable performance status (PS). Despite the increasing clinical data on osimertinib, evidence for its use in patients with impaired PS remains limited. Therefore, a multicenter phase II trial (OPEN/TORG2040) was conducted to evaluate the efficacy and safety of first-line osimertinib treatment in patients with <em>EGFR</em> mutation-positive NSCLC and a poor PS.</div></div><div><h3>Methods</h3><div>Patients with previously untreated advanced NSCLC harboring <em>EGFR</em>-sensitizing mutations and PS of 2 to 4 were enrolled. Osimertinib (80 mg once daily) was orally administered to eligible patients. The primary end point was objective response rate. The secondary end points were disease control rate, PS improvement rate, patient-reported outcomes, and safety.</div></div><div><h3>Results</h3><div>Between February 2021 and February 2022, 30 patients with poor PS (22 with a PS of 2, six with a PS of 3, and two with a PS of 4) were enrolled. The median age was 75 (range, 41–92) years, and 18 patients had brain metastases. The objective response rate was 63.3% (90% confidence interval, 46.7%–77.9%; one-sided, <em>p</em> = 0.033). Disease control and PS improvement rates were 93.3% and 63.3%, respectively. Global health status/QoL also improved. Median progression-free and overall survival were 8.0 and 25.4 months, respectively. Eight patients (26.7%) experienced serious adverse events leading to discontinuation, and six (20.0%) experienced interstitial lung disease.</div></div><div><h3>Conclusions</h3><div>This prospective study confirmed the efficacy of first-line osimertinib treatment in patients with <em>EGFR</em> mutation-positive NSCLC and poor PS, highlighting the need for interstitial lung disease risk management.</div></div><div><h3>Trial registration number</h3><div>Japan Registry of Clinical Trials Identifier: jRCTs041200100.</div></div>","PeriodicalId":17515,"journal":{"name":"Journal of Thoracic Oncology","volume":"20 5","pages":"Pages 665-675"},"PeriodicalIF":21.0,"publicationDate":"2025-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142927273","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Amivantamab Plus Lazertinib in Patients With EGFR-Mutant NSCLC After Progression on Osimertinib and Platinum-Based Chemotherapy: Results From CHRYSALIS-2 Cohort A","authors":"Benjamin Besse MD, PhD ,&nbsp;Koichi Goto MD, PhD ,&nbsp;Yongsheng Wang MD ,&nbsp;Se-Hoon Lee MD, PhD ,&nbsp;Melina E. Marmarelis MD ,&nbsp;Yuichiro Ohe MD, PhD ,&nbsp;Reyes Bernabe Caro MD ,&nbsp;Dong-Wan Kim MD, PhD ,&nbsp;Jong-Seok Lee MD, PhD ,&nbsp;Sophie Cousin MD, MSc ,&nbsp;Eiki Ichihara MD, PhD ,&nbsp;Yongsheng Li MD, PhD ,&nbsp;Luis Paz-Ares MD, PhD ,&nbsp;Akira Ono MD, PhD ,&nbsp;Rachel E. Sanborn MD ,&nbsp;Naohiro Watanabe MD ,&nbsp;Maria Jose de Miguel MD, PhD ,&nbsp;Carole Helissey MD, PhD ,&nbsp;Catherine A. Shu MD ,&nbsp;Alexander I. Spira MD, PhD ,&nbsp;Byoung Chul Cho MD, PhD","doi":"10.1016/j.jtho.2024.12.029","DOIUrl":"10.1016/j.jtho.2024.12.029","url":null,"abstract":"<div><h3>Introduction</h3><div>Treatment options for patients with <em>EGFR</em>-mutated NSCLC with disease progression on or after osimertinib and platinum-based chemotherapy are limited.</div></div><div><h3>Methods</h3><div>CHRYSALIS-2 cohort A evaluated amivantamab plus lazertinib in patients with <em>EGFR</em> exon 19 deletion- or L858R-mutated NSCLC with disease progression on or after osimertinib and platinum-based chemotherapy. Primary end point was investigator-assessed objective response rate (ORR). The patients received 1050 mg of intravenous amivantamab (1400 mg if ≥ 80 kg) plus 240 mg of oral lazertinib.</div></div><div><h3>Results</h3><div>In cohort A (N = 162), the investigator-assessed ORR was 28% (95% confidence interval [CI]: 22–36). The blinded independent central review–assessed ORR was 35% (95% CI: 27–42), with a median duration of response of 8.3 months (95% CI: 6.7–10.9) and a clinical benefit rate of 58% (95% CI: 50–66). At a median follow-up of 12 months, 32 of 56 responders (57%) achieved a duration of response of more than or equal to 6 months. Median progression-free survival by blinded independent central review was 4.5 months (95% CI: 4.1–5.8); median overall survival was 14.8 months (95% CI: 12.2–18.0). Preliminary evidence of central nervous system antitumor activity was reported in seven patients with baseline brain lesions and no previous brain radiation or surgery. Exploratory biomarker analyses using next-generation sequencing of circulating tumor DNA revealed responses in patients with and without <em>EGFR</em><em>-</em> or <em>MET</em>-dependent resistance. The most frequent adverse events were rash (grouped term; 81%), infusion-related reaction (68%), and paronychia (52%). The most common grade greater than or equal to 3 treatment-related adverse events were rash (grouped term; 10%), infusion-related reaction (9%), and hypoalbuminemia (6%).</div></div><div><h3>Conclusions</h3><div>For patients with limited treatment options, amivantamab plus lazertinib demonstrated an antitumor activity with a safety profile characterized by EGFR- or MET-related adverse events, which were generally manageable.</div></div>","PeriodicalId":17515,"journal":{"name":"Journal of Thoracic Oncology","volume":"20 5","pages":"Pages 651-664"},"PeriodicalIF":21.0,"publicationDate":"2025-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142927287","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Corrigendum to ‘OA09.04 Osimertinib with or without SRS for Brain Metastases from EGFRm NSCLC: Pooled Analysis of Two RCTs’ [Journal of Thoracic Oncology Vol. 19 No. 10S (2024) S28]","authors":"C. Ho ,&nbsp;Y.Y. Soon ,&nbsp;A. Nichol ,&nbsp;K. Robledo ,&nbsp;A. Sahgal ,&nbsp;M. Pinkham ,&nbsp;B. Melosky ,&nbsp;Y. Huang ,&nbsp;A. Parmar ,&nbsp;B. Solomon ,&nbsp;M. Liu ,&nbsp;I.W.K. Tham ,&nbsp;A. Sacher ,&nbsp;J.C.S. Tey ,&nbsp;I. Menjak ,&nbsp;C.N. Leong ,&nbsp;D. Shultz ,&nbsp;W.Y. Koh ,&nbsp;M. Doherty ,&nbsp;Y. Ang ,&nbsp;F. Hegi-Johnson","doi":"10.1016/j.jtho.2025.02.016","DOIUrl":"10.1016/j.jtho.2025.02.016","url":null,"abstract":"","PeriodicalId":17515,"journal":{"name":"Journal of Thoracic Oncology","volume":"20 5","pages":"Page 680"},"PeriodicalIF":21.0,"publicationDate":"2025-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143917725","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Refining Surgical Decision-Making for Elderly Patients With Lung Cancer: Recognized Risks, Unmet Needs","authors":"Feng Wang MD,&nbsp;Minwei Bao PhD,&nbsp;Lei Zhu PhD","doi":"10.1016/j.jtho.2025.02.008","DOIUrl":"10.1016/j.jtho.2025.02.008","url":null,"abstract":"","PeriodicalId":17515,"journal":{"name":"Journal of Thoracic Oncology","volume":"20 5","pages":"Pages e62-e63"},"PeriodicalIF":21.0,"publicationDate":"2025-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143916811","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}